Naltrexone extended-release injection: an option for the management of opioid abuse

References

• Substance Abuse and Mental Health Services AdministrationResults from the 2010 National Survey on Drug Use and Health: Summary of National Findings NSDUH Series H-41 HHS Publication No. (SMA) 11-4658Rockville, MDSubstance Abuse and Mental Health Services Administration2011
   Google Scholar
• StagnittiMNTrends in Outpatient Prescription Analgesics Utilization and Expenditures for the US Civilian Noninstitutionalized Population, 1996 and 2006Rockville, MDAgency for Healthcare Research and Quality2009
   Google Scholar
• Centers for Disease Control and Prevention (CDC)Drug overdose deaths: Florida, 2003–2009MMWR Morb Mortal Wkly Rep2011602686987221734633
   PubMedGoogle Scholar
• GoldsteinAHerreraJHeroin addicts and methadone treatment in Albuquerque: a 22-year follow-upDrug Alcohol Depend19954021391508745136
   PubMed Web of Science ®Google Scholar
• HulseGKEnglishDRMilneEHolmanCDThe quantification of mortality resulting from the regular use of illicit opiatesAddiction199994222122910396790
   PubMed Web of Science ®Google Scholar
• DarkeSRossJSuicide among heroin users: rates, risk factors and methodsAddiction200297111383139412410779
   PubMed Web of Science ®Google Scholar
• SchneiderJPMatthewsMJamisonRNAbuse-deterrent and tamper-resistant opioid formulations: what is their role in addressing prescription opioid abuse?CNS Drugs2010241080581020839893
   PubMed Web of Science ®Google Scholar
• HamedEMoeDDevelopment of tamper deterrent formulations: state of the pharmaceutical industryCurr Drug Abuse Rev20103313914621054261
   PubMedGoogle Scholar
• RaffaRBPergolizziJVJrOpioid formulations designed to resist/deter abuseDrugs201070131657167520731474
   PubMed Web of Science ®Google Scholar
• KleberHDPharmacologic treatments for opioid dependence: detoxification and maintenance optionsDialogues Clin Neurosci20079445547018286804
   PubMedGoogle Scholar
• CastellsXKostenTRCapellàDVidalXColomJCasasMEfficacy of opiate maintenance therapy and adjunctive interventions for opioid dependence with comorbid cocaine use disorders: a systematic review and meta-analysis of controlled clinical trialsAm J Drug Alcohol Abuse200935533934920180662
   PubMed Web of Science ®Google Scholar
• AmatoLMinozziSDavoliMVecchiSFerriMMMayetSPsychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxificationCochrane Database Syst Rev20084CD00503118843675
   PubMedGoogle Scholar
• WittchenHUApeltSMSoykaMFeasibility and outcome of substitution treatment of heroin-dependent patients in specialized substitution centers and primary care facilities in Germany: a naturalistic study in 2694 patientsDrug Alcohol Depend200895324525718337025
   PubMed Web of Science ®Google Scholar
• MattickRPBreenCKimberJDavoliMMethadone maintenance therapy versus no opioid replacement therapy for opioid dependenceCochrane Database Syst Rev20093CD00220919588333
   PubMed Web of Science ®Google Scholar
• Van den BrinkWHaasenCEvidenced-based treatment of opioid-dependent patientsCan J Psychiatry2006511063564617052031
   PubMed Web of Science ®Google Scholar
• SoykaMKranzlerHRvan den BrinkWKrystalJMöllerHJKasperSWFSBP Task Force on TreatmentGuidelines for Substance Use DisordersThe World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of substance use and related disorders: Part 2. Opioid dependenceWorld J Biol Psychiatry201112316018721486104
   PubMed Web of Science ®Google Scholar
• NichollsLBragawLRuetschCOpioid dependence treatment and guidelinesJ Manag Care Pharm2010161 Suppl BS14S2120146550
   PubMed Web of Science ®Google Scholar
• MattickRPKimberJBreenCDavoliMBuprenorphine maintenance versus placebo or methadone maintenance for opioid dependenceCochrane Database Syst Rev20032CD00220712804429
   PubMedGoogle Scholar
• MattickRPBreenCKimberJDavoliMMethadone maintenance therapy versus no opioid replacement therapy for opioid dependenceCochrane Database Syst Rev20032CD00220912804430
   PubMedGoogle Scholar
• World Health Organization (WHO)Guidelines for the psychoso-cially assisted pharmacological treatment of opioid dependenceDepartment of Mental Health and Substance AbuseAbuseGenevaWHO Press20091110
   Google Scholar
• MathersBMDegenhardtLAliHHIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverageLancet201037597191014102820189638
   PubMed Web of Science ®Google Scholar
• FriedmannPDLemonSCSteinMDD’AunnoTAAccessibility of addiction treatment: results from a national survey of outpatient substance abuse treatment organizationsHealth Serv Res200338388790312822917
   PubMed Web of Science ®Google Scholar
• PetersonJASchwartzRPMitchellSGWhy don’t out-of-treatment individuals enter methadone treatment programmes?Int J Drug Policy2010211364218805686
   PubMed Web of Science ®Google Scholar
• ReeceASDiffering age related trajectories of dysfunction in several organ systems in opiate dependenceAging Clin Exp Res Epub2212011
   Web of Science ®Google Scholar
• ToskulkaoTPornchaiRAkkarapatumwongVVatanatunyakumSGovitrapongPAlteration of lymphocyte opioid receptors in methadone maintenance subjectsNeurochem Int201056228529019913582
   PubMed Web of Science ®Google Scholar
• MartinWRJasinskiDRManskyPANaltrexone, an antagonist for the treatment of heroin dependence: effects in manArch Gen Psychiatry19732867847914707988
   PubMed Web of Science ®Google Scholar
• MelloNKMendelsonJHKuehnleJCSellersMSOperant analysis of human heroin self-administration and the effects of naltrexoneJ Pharmacol Exp Ther1981216145547452507
   PubMed Web of Science ®Google Scholar
• WalshSLSullivanJTPrestonKLGarnerJEBigelowGEEffects of naltrexone on response to intravenous cocaine, hydromorphone and their combination in humansJ Pharmacol Exp Ther199627925245388930154
   PubMed Web of Science ®Google Scholar
• MinozziSAmatoLVecchiSDavoliMKirchmayerUVersterAOral naltrexone maintenance treatment for opioid dependenceCochrane Database Syst Rev20061CD00133316437431
   PubMedGoogle Scholar
• MinozziSAmatoLVecchiSDavoliMKirchmayerUVersterAOral naltrexone maintenance treatment for opioid dependenceCochrane Database Syst Rev20114CD00133321491383
   PubMedGoogle Scholar
• AmatoLMinozziSDavoliMVecchiSFerriMMMayetSPsychosocial combined with agonist maintenance treatments versus ago-nist maintenance treatments alone for treatment of opioid dependenceCochrane Database Syst Rev20084CD00414718843654
   PubMedGoogle Scholar
• CarrollKMBallSANichCTargeting behavioral therapies to enhance naltrexone treatment of opioid dependence: efficacy of contingency management and significant other involvementArch Gen Psychiatry200158875576111483141
   PubMed Web of Science ®Google Scholar
• Fals-StewartWO’FarrellTJBehavioral family counseling and nal-trexone for male opioid-dependent patientsJ Consult Clin Psychol200371343244212795568
   PubMed Web of Science ®Google Scholar
• ComerSDSullivanMAHulseGKSustained-release naltrexone: novel treatment for opioid dependenceExpert Opin Investig Drugs200716812851294
   PubMed Web of Science ®Google Scholar
• BrewerCStreelERecent developments in naltrexone implants and depot injections for opiate abuse: the new kid on the block is approaching adulthoodAdicciones201022428529121152846
   PubMed Web of Science ®Google Scholar
• KellyKIMcBrideANaltrexone implantsBr J Psychiatry2010196177 author reply 7720044669
   PubMed Web of Science ®Google Scholar
• KunøeNLobmaierPVederhusJKNaltrexone implants after in-patient treatment for opioid dependence: randomised controlled trialBr J Psychiatry2009194654154619478295
   PubMed Web of Science ®Google Scholar
• WaalHFrogopsahlGOlsenLChristophersenASMørlandJNaltrexone implants: duration, tolerability and clinical usefulness; a pilot studyEur Addict Res200612313814416778434
   PubMed Web of Science ®Google Scholar
• ComerSDCollinsEDKleberHDNuwayserESKerriganJHFischmanMWDepot naltrexone: long-lasting antagonism of the effects of heroin in humansPsychopharmacology (Berl)2002159435136011823887
   PubMed Web of Science ®Google Scholar
• ComerSDSullivanMAYuEInjectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trialArch Gen Psychiatry200663221021816461865
   PubMed Web of Science ®Google Scholar
• BrooksACComerSDSullivanMALong-acting injectable versus oral naltrexone maintenance therapy with psychosocial intervention for heroin dependence: a quasi-experimentJ Clin Psychiatry201071101371137820673549
   PubMed Web of Science ®Google Scholar
• KrupitskyENunesEVLingWIlleperumaAGastfriendDRSilvermanBLInjectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trialLancet201137797761506151321529928
   PubMed Web of Science ®Google Scholar
• FishmanMJWinstanleyELCurranEGarrettSSubramaniamGTreatment of opioid dependence in adolescents and young adults with extended release naltrexone: preliminary case-series and feasibilityAddiction201010591669167620626723
   PubMed Web of Science ®Google Scholar
• DeFulioAEverlyJJLeoutsakosJMEmployment-based reinforcement of adherence to an FDA approved extended release formulation of naltrexone in opioid-dependent adults: a randomized controlled trialDrug Alcohol Depend Epub7202011
   Web of Science ®Google Scholar
• EverlyJJDeFulioAKoffarnusMNEmployment-based reinforcement of adherence to depot naltrexone in unemployed opioid-dependent adults: a randomized controlled trialAddiction201110671309131821320227
   PubMed Web of Science ®Google Scholar
• LobmaierPKornørHKunøeNBjørndalASustained-release naltrexone for opioid dependenceCochrane Database Syst Rev20082CD00614018425938
   PubMedGoogle Scholar
• LobmaierPPKunøeNGossopMWaalHNaltrexone depot formulations for opioid and alcohol dependence: a systematic reviewCNS Neurosci Ther Epub9232010
   Web of Science ®Google Scholar
• MalcolmRO’NeilPMSexauerJDRiddleFECurreyHSCountsCA controlled trial of naltrexone in obese humansInt J Obes1985953473533908352
   PubMed Web of Science ®Google Scholar
• Vivitrol (naltrexone for extended-release injectable suspension) [prescribing information]Dublin, IrelandAlkermes Inc2010
   Google Scholar
• BrewerCWongVSNaltrexone: report of lack of hepatotoxicity in acute viral hepatitis, with a review of the literatureAddict Biol200491818715203443
   PubMed Web of Science ®Google Scholar
• YenMHKoHCTangFILuRBHongJSStudy of hepatotoxicity of naltrexone in the treatment of alcoholismAlcohol200638211712016839858
   PubMed Web of Science ®Google Scholar
• GarbuttJCEfficacy and tolerability of naltrexone in the management of alcohol dependenceCurr Pharm Des201016192091209720482515
   PubMed Web of Science ®Google Scholar
• RamdurgSAmbekarALalRSexual dysfunction among male patients receiving buprenorphine and naltrexone maintenance therapy for opioid dependenceJ Sex Med Epub322011
   Web of Science ®Google Scholar
• SirohiSKumarPYoburnBCMu-opioid receptor up-regulation and functional supersensitivity are independent of antagonist efficacyJ Pharmacol Exp Ther2007323270170717698975
   PubMed Web of Science ®Google Scholar
• ZakiPAKeithDEJrBrineGACarrollFIEvansCJLigand-induced changes in surface mu-opioid receptor number: relationship to G protein activation?J Pharmacol Exp Ther200029231127113410688632
   PubMed Web of Science ®Google Scholar
• RajashekaraVPatelCNPatelKPurohitVYoburnBCChronic opioid antagonist treatment dose-dependently regulates mu-opioid receptors and trafficking proteins in vivoPharmacol Biochem Behav200375490991312957235
   PubMed Web of Science ®Google Scholar
• YoburnBCShahSChanKDuttaroyADavisTSupersensitivity to opioid analgesics following chronic opioid antagonist treatment: relationship to receptor selectivityPharmacol Biochem Behav1995512–35355397667382
   PubMed Web of Science ®Google Scholar
• LesscherHMBaileyABurbachJPVan ReeJMKitchenIGerritsMAReceptor-selective changes in mu-, delta- and kappa-opioid receptors after chronic naltrexone treatment in miceEur J Neurosci20031751006101212653976
   PubMed Web of Science ®Google Scholar
• PatelCNRajashekaraVPatelKPurohitVYoburnBCChronic opioid antagonist treatment selectively regulates trafficking and signaling proteins in mouse spinal cordSynapse2003501677612872295
   PubMed Web of Science ®Google Scholar
• YoburnBCInturrisiCEModification of the response to opioid and nonopioid drugs by chronic opioid antagonist treatmentLife Sci19884218168916963362035
   PubMed Web of Science ®Google Scholar
• YoburnBCKreuscherSPInturrisiCESierraVOpioid receptor upregulation and supersensitivity in mice: effect of morphine sensitivityPharmacol Biochem Behav19893237277312544906
   PubMed Web of Science ®Google Scholar
• FishmanMPrecipitated withdrawal during maintenance opioid blockade with extended release naltrexoneAddiction200810381399140118855831
   PubMed Web of Science ®Google Scholar
• DigiustoEShakeshaftARitterAO’BrienSMattickRPNEPOD Research GroupSerious adverse events in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD)Addiction200499445046015049745
   PubMed Web of Science ®Google Scholar
• RitterAJNaltrexone in the treatment of heroin dependence: relationship with depression and risk of overdoseAust N Z J Psychiatry200236222422811982544
   PubMed Web of Science ®Google Scholar
• O’BrienBCodyCAnalgesia and sedation in the presence of a naltrexone implant: a novel pharmacological challengeEur J Emerg Med200613531531616969243
   PubMed Web of Science ®Google Scholar
• WardJMattickRPHallWThe effectiveness of methadone maintenance treatment: an overviewDrug Alcohol Rev199413332733516818345
   PubMedGoogle Scholar
• FiellinDAMooreBASullivanLELong-term treatment with buprenorphine/naloxone in primary care: results at 2–5 yearsAm J Addict200817211612018393054
   PubMed Web of Science ®Google Scholar
• HubbardRLMarsdenMECavanaughERachalJVGinzburgHMRole of drug-abuse treatment in limiting the spread of AIDSRev Infect Dis19881023773843259712
   PubMedGoogle Scholar
• SimpsonDDJoeGWBroomeKMA national 5-year follow-up of treatment outcomes for cocaine dependenceArch Gen Psychiatry200259653854412044196
   PubMed Web of Science ®Google Scholar
• SimpsonDDTreatment for drug abuse: follow-up outcomes and length of time spentArch Gen Psychiatry19813888758807259424
   PubMed Web of Science ®Google Scholar
• HubbardRLCraddockSGAndersonJOverview of 5-year followup outcomes in the drug abuse treatment outcome studies (DATOS)J Subst Abuse Treat200325312513414670518
   PubMed Web of Science ®Google Scholar
• GottheilESterlingRCWeinsteinSPDiminished illicit drug use as a consequence of long-term methadone maintenanceJ Addict Dis199312445578292639
   PubMedGoogle Scholar
• MaremmaniIPaniPPPaciniMPerugiGSubstance use and quality of life over 12 months among buprenorphine maintenance-treated and methadone maintenance-treated heroin-addicted patientsJ Subst Abuse Treat72007331919817588494
   PubMed Web of Science ®Google Scholar